Document Detail


FDG-PET/CT in lung cancer: an update.
MedLine Citation:
PMID:  19955789     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The prognosis of lung cancer patients mostly depends on the stage at which the disease is diagnosed. Contrast-enhanced CT (ceCT) and MRI play a significant role in initial staging, but often the morphological information is insufficient when compared to the metabolic or molecular information obtained by positron emission tomography (PET). [18]F-fluorine deoxyglucose (FDG) is based upon the increased demand of ATP leading to increased consumption of glucose in the tumor tissues. FDG-PET/CT has been proven to be of immense value in the initial diagnosis, evaluation of therapy reponse, detection of recurrent tumor, radiation therapy planning and in the multidisciplinary management of patients with non-small cell lung cancer as well as in patients with small cell lung cancer. The aim of this article is to present a concise summary of the present status of FDG-PET/CT.
Authors:
Richard P Baum; Cyprian Swietaszczyk; Vikas Prasad
Related Documents :
11198529 - Limbic encephalitis investigated by 18fdg-pet and 3d mri.
17021839 - Unsuspected fdg-pet findings in the follow-up of patients with lymphoma.
21209729 - Acute pancreatitis secondary to a perivaterian duodenal diverticular abscess.
19289439 - Novel strategy for a cocktail 18f-fluoride and 18f-fdg pet/ct scan for evaluation of ma...
11839069 - 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monito...
2920739 - [18f]fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advance...
20498609 - Single-phase dual-energy ct allows for characterization of renal masses as benign or ma...
16360859 - Intrarater reliability in the ultrasound diagnosis of medial and lateral orbital wall f...
6869059 - Quality assurance in radiographic imaging included in the film marking procedure.
Publication Detail:
Type:  Journal Article; Review     Date:  2009-11-24
Journal Detail:
Title:  Frontiers of radiation therapy and oncology     Volume:  42     ISSN:  0071-9676     ISO Abbreviation:  Front Radiat Ther Oncol     Publication Date:  2010  
Date Detail:
Created Date:  2009-12-03     Completed Date:  2010-03-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0125544     Medline TA:  Front Radiat Ther Oncol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  15-45     Citation Subset:  IM    
Copyright Information:
Copyright 2010 S. Karger AG, Basel.
Affiliation:
Department of Nuclear Medicine/Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany. info@rpbaum.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Fluorodeoxyglucose F18 / diagnostic use*
Humans
Lung Neoplasms / pathology,  radiography*,  radionuclide imaging*
Positron-Emission Tomography*
Prognosis
Radiopharmaceuticals / diagnostic use*
Tomography, X-Ray Computed*
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic Factors in Histopathology of Lung Cancer.
Next Document:  Whole-Body Magnetic Resonance Imaging for Staging of Lung Cancer.